ABSTRACTS
Evaluation of alcohol use behavior among patients cured in Georgia’s HCV elimination program (preliminary results)
2022 Y
Identifying risk factors for HCV transmission in the country of Georgia: A case-control study
2022 Y
Improvement of health-related quality of life (HQoL) after HCV treatment with direct acting antivirals (DAAs) in Georgia
2022 Y
Epidemiology of hepatitis B virus infection among hepatitis C virus (HCV) infected patients treated within the HCV elimination program in Georgia
2021 Y
Evaluation of Hepatitis C treatment outcome among people who inject drugs in Georgia
2019 Y
Hepatitis C treatment integration with harm reduction services in Georgia: preliminary findings
2019 Y
Trust of the Georgia National HCV Elimination Program among reproductive aged women
2019 Y
Reversal of liver damage among HCV infected persons with advanced liver disease: Two-year follow-up from the HCV elimination program, Georgia
2018 Y
Long-term health outcome among HCV patients with advanced liver fibrosis treated through HCV elimination program in Georgia
2018 Y
Attitude of staff regarding integrated hepatitis C treatment at eight harm reduction centers in Georgia
2018 Y
Outcomes of hepatitis C antiviral treatment among PWIDs in Georgia
2018 Y
Low HCV reinfection rate after treatment in people who infect drugs (PWID) from a prospective cohort in Tbilisi, Georgia
2018 Y
Factors associated with sustained viral response among HCV genotype 2 patients treated with direct acting antivirals within HCV elimination program in Georgia
2018 Y
Characteristics of patients with missing sustained virologic response (SVR) data, elimination program in Georgia
2018 Y
Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia
2018 Y